For more information about the LIFE-BTK study.
No. Patient enrollment is closed for both LIFE-BTK and LIFE-BTK PK SUB‑STUDY.
This is a study to test the Esprit™ BTK resorbable scaffold, a new device for the treatment of CLI. The device is implanted in the artery immediately after a balloon angioplasty, providing support and preventing the vessel from reclosing. The scaffold releases a drug into the artery over a few months that promotes healing and keeps the artery open. The device is made of a material that dissolves over time and will be gone from your body in about 3 years.
Patients in this study will have multiple visits over 5 years.
The LIFE-BTK PK SUB-STUDY will evaluate 9 patients from around the world.
Clinical studies are very important to advancing medicine and can help others lead healthier lives. Some people join a study because the treatments they have tried for their health problem did not work or because there is no treatment available. By being part of a clinical trial, participants may gain access to new treatments before they are widely available.